Global Head and Neck Squamous Cell Carcinoma Market 2018-2026 Size, Share By Key Drivers, Future Growth, Players, Segmentation, Opportunity Analysis
Jul 11, 2018
New Report on Global Head and Neck Squamous Cell Carcinoma Market added to Orbisresearch.com database. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.
Dallas, United States - July 11, 2018 /MarketersMedia/ —
Global Head and Neck Squamous Cell Carcinoma Market 2018-2026:
The head and neck (HNC) cancer market is expected to experience significant growth between 2016 and 2026 within the seven major markets (US, France, Germany, Italy, Spain, UK and Japan). The main growth drivers will be attributed to the incorporation of immune-checkpoint inhibitors into the first-line recurrent/metastatic and locally-advanced disease treatment paradigms. Due to the high cost of immunotherapy regimens, this is expected to cause large growth within the head and neck cancer market.
Up until the approvals of Opdivo in the 7MM and Keytruda in the US during 2016 for the platinum-refractory recurrent/metastatic population, Erbitux was the only targeted agent ion the market, whilst the rest of the market was dominated by generic chemotherapy. Now that programmed cell death protein 1 (PD-1) inhibitors have penetrated into the second-line, label-expansions into earlier lines and in combinations with other immuno-oncology (IO) agents are expected during the forecast period. This will significantly expand the eligible population that can receive these premium-priced immunotherapies - The HNC competitive landscape is expected to experience a significant change, a new standard of care is predicted to be established in eight pipeline agents are expected to launch before 2026.
Get sample copy of Global Head and Neck Squamous Cell Carcinoma Market report@ http://orbisresearch.com/contacts/request-sample/2189669
Key Players:
• Merck & Co.
• Bristol-Myers Squibb Co.
• Eli Lilly
• Taiho
• AstraZeneca
• Pfizer
• Incyte
• Tessa Therapeutics
• Boehringer Ingelheim
• CEL-SCI
• Pierre Fabre
Scope:
- Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized HNC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.
- Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized HNC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.
Make an inquiry before buying Global Head and Neck Squamous Cell Carcinoma Market@ http://orbisresearch.com/contacts/enquiry-before-buying/2189669
Key Questions Answered
- How will the implementation of IO agents into earlier-lines of therapy affect the current treatment paradigm and which combinations are expected to have the greatest impact and highest chance of an approval?
- The head and neck cancer market is characterized by a number of unmet needs. What are the main unmet needs in this market? Will the pipeline drugs under development fulfil these needs?
- Eight late-stage pipeline agents are going to enter the head and neck cancer market from 2017 onwards. Will the late-stage drugs make a significant impact on the head and neck cancer market? Which of these drugs will have the highest peak sales, and why?
Reasons to buy:
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HNC market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HNC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Get more information about Global Head and Neck Squamous Cell Carcinoma Market report@ http://orbisresearch.com/reports/index/head-and-neck-squamous-cell-carcinoma-opportunity-analysis-and-forecast-to-2026
Key Points from Table of Content:
2 Executive Summary
2.1 Dramatic Growth Is Projected for the 7MM HNSCC Market from 2016 to 2026
2.2 Immuno-oncology Drugs to Extend Their Reach to All HNSCC Market Segments
2.3 High Unmet Needs for Biomarker of Response in the HNSCC Market
2.4 Opportunities Remain for Developers Who Launch Novel Treatments for HNSCC Subpopulations and Identify New Druggable Targets
2.5 What Do the Physicians Think?
3 Introduction
4 Disease Overview
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods - Population
5.4.3 Forecast Assumptions and Methods - Diagnosed Incident Cases of HNCs
5.4.4 Forecast Assumptions and Methods - Five-Year Diagnosed Prevalent Cases of HNCs
5.4.5 Forecast Assumptions and Methods - Diagnosed Incident Cases of HNCs by Histology Distribution
5.4.6 Forecast Assumptions and Methods - Diagnosed Incident Cases of HNC by Clinical Stages at Diagnosis for Squamous Cell Carcinoma
5.4.7 Forecast Assumptions and Methods - Diagnosed Incident Cases of Oropharynx Cancer by Risk Factor (HPV+ and HPV-)
5.4.8 Forecast Assumptions and Methods - Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factor (EBV+)
5.5 Epidemiological Forecast for HNCs (2016-2026)
5.5.1 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer
5.5.2 Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer
5.5.3 Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer
5.5.4 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Histology Distribution
5.5.5 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma
5.5.6 Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer
5.5.7 Diagnosed Incident Cases of Oropharynx Cancer by Histology Distribution and by Risk Factor (HPV)
5.5.8 Diagnosed Incident Cases of Nasopharynx Cancer by Histology Distribution and by Risk Factor (EBV)
5.5.9 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
5.5.10 Age-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
5.5.11 Sex-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
6 Current Treatment Options
7 Unmet Needs Assessment and Opportunity Analysis
8 R&D Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Info:
Name: Hector Costello
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A.
Phone: +1 (214) 884-6817
For more information, please visit http://www.orbisresearch.com
Source: MarketersMedia
Release ID: 375498
More News
What’s the Right “Level of Care” for A.I.?
Another executive departed OpenAI, raising questions about the company’s commitment to safety.
CNN C.E.O. Mark Thompson Says He Will Stay On Under New Owner Skydance
Mark Thompson told the network’s employees that he had faith that David Ellison, the chief executive of Skydance, would support “independent news that CNN has always stood for.”
Russians Snap Up Chinese E.V.s as Ukrainian Attacks Make Fuel Scarce
As Ukraine increasingly takes the war to Russia, the effects may be most visible on the roads.
BT agrees rescue deal to buy broadband operator TalkTalk
The takeover still needs to be approved by the regulator, but would give certainty to TalkTalk's millions of customers
Why are data centres such a big deal in Scotland?
At least 23 huge data centres are planned in Scotland, causing significant concern for campaigners.
Trump chooses top spy boss to run new AI taskforce
The US president said his national intelligence chief will lead the group as worries over AI grow.
Average five-year mortgage rate hits 6% for first time in three years
The cost of a new fixed-rate mortgage has been rising in recent weeks as lenders face higher costs.
5 Challenges David Ellison Faces as He Snags His Hollywood Prize
The tech scion has given his combination of Warner Bros. Discovery and Paramount a new name: Skydance. Now he must make tough decisions about news, movies, streaming, sports and debt.
How to Get a VAT Tax Refund
Here are the steps to get your money back on VAT taxes, which are widespread in Europe and are bundled into the costs of certain items that travelers take home with them.
How to Get a VAT Tax Refund
Here are the steps to get your money back on VAT taxes, which are widespread in Europe and are bundled into the costs of certain items that travelers take home with them.
To Make More Money, Rolls-Royce Is Aiming Higher on Price, Not Production
The luxury carmaker is expanding its factory in Britain to focus on rarefied custom cars. First up is a $3.5 million-plus electric roadster.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.